Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 12, 2019Scientific ReportsOpen Access

Murine infection with bioluminescent Leishmania infantum axenic amastigotes applied to drug discovery

View Full Paper
Ask AI
Bookmark
Share

Authors

DCDavid CostaUniversidade do PortoPCPedro CecílioNational Institutes of HealthNSNuno SantarémUniversidade do Porto

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Costa et al. (2019) studied this question.

synapsesocial.com/papers/6a99ae888ad511aa02da6e31https://doi.org/10.1038/s41598-019-55474-3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Luciferase-Expressing Leishmania infantum Allows the Monitoring of Amastigote Population Size, In Vivo, Ex Vivo and In Vitro2011 · 76 citations
  2. 2Drug resistance and treatment failure in leishmaniasis: A 21st century challenge2017 · 990 citations
  3. 3High-Throughput Screening Platform for Natural Product–Based Drug Discovery Against 3 Neglected Tropical Diseases: Human African Trypanosomiasis, Leishmaniasis, and Chagas Disease2014 · 86 citations
  4. 4Axenic cultivation of amastigotes of<i>Leishmania donovani</i>and<i>Leishmania major</i>and their infectivity1992 · 32 citations
  5. 5Generation of Luciferase-Expressing Leishmania infantum chagasi and Assessment of Miltefosine Efficacy in Infected Hamsters through Bioimaging2015 · 38 citations